Compare DH & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DH | XBIT |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.9M | 74.4M |
| IPO Year | 2021 | 2015 |
| Metric | DH | XBIT |
|---|---|---|
| Price | $0.81 | $2.30 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $3.08 | N/A |
| AVG Volume (30 Days) | ★ 607.8K | 33.4K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.28 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $241,521,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.62 | $2.09 |
| 52 Week High | $4.70 | $3.61 |
| Indicator | DH | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 48.87 | 45.52 |
| Support Level | $0.80 | $2.26 |
| Resistance Level | $1.04 | $2.42 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 58.71 | 28.09 |
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.